Literature DB >> 17227961

Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism.

Sjur Reppe1, Lis Stilgren, Bo Abrahamsen, Ole K Olstad, Fadila Cero, Kim Brixen, Lise Sofie Nissen-Meyer, Kaare M Gautvik.   

Abstract

In primary hyperparathyroidism (PHPT), excess PTH secretion by adenomatous or hyperplastic parathyroid glands leads to elevated serum [Ca(2+)]. Patients present complex symptoms of muscular fatigue, various neuropsychiatric, neuromuscular, and cardiovascular manifestations, and, in advanced disease, kidney stones and metabolic bone disease. Our objective was to characterize changes in muscle and hematopoietic gene expression in patients with reversible mild PHPT after parathyroidectomy and possibly link molecular pathology to symptoms. Global mRNA profiling using Affymetrix gene chips was carried out in biopsies obtained before and 1 yr after parathyroidectomy in seven patients discovered by routine blood [Ca(2+)] screening. The tissue distribution of PTH receptor (PTHR1 and PTHR2) mRNAs were quantitated using real-time RT-PCR in unrelated persons to define PTH target tissues. Of about 10,000 expressed genes, 175 muscle, 169 hematological, and 99 bone-associated mRNAs were affected. Notably, the major part of muscle-related mRNAs was increased whereas hematological mRNAs were predominantly decreased during disease. Functional and molecular network analysis demonstrated major alterations of several tissue characteristic groups of mRNAs as well as those belonging to common cell signaling and major metabolic pathways. PTHR1 and PTHR2 mRNAs were more abundantly expressed in muscle and brain than in hematopoietic cells. We suggest that sustained stimulation of PTH receptors present in brain, muscle, and hematopoietic cells have to be considered as one independent, important cause of molecular disease in PHPT leading to profound alterations in gene expression that may help explain symptoms like muscle fatigue, cardiovascular pathology, and precipitation of psychiatric illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227961     DOI: 10.1152/ajpendo.00487.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  10 in total

1.  Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Authors:  T Sikjaer; L Rolighed; A Hess; A Fuglsang-Frederiksen; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2014-04-01       Impact factor: 4.507

2.  Surgical cure of primary hyperparathyroidism ameliorates gastroesophageal reflux symptoms.

Authors:  James Norman; Douglas Politz; Jose Lopez; Deva Boone; Alexander Stojadinovic
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

3.  Does PTH Replacement Therapy Improve Quality of Life in Patients With Chronic Hypoparathyroidism?

Authors:  Karen K Winer
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

4.  Muscle function is impaired in patients with "asymptomatic" primary hyperparathyroidism.

Authors:  Lars Rolighed; Anne Kristine Amstrup; Niels Frederik Breum Jakobsen; Tanja Sikjaer; Leif Mosekilde; Peer Christiansen; Lars Rejnmark
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

5.  The expression of PTHLH in human gastric mucosa enterochromaffin-like cells.

Authors:  Cuiping Liu; Jianting Chen; Yu Guo; Lisheng Yang; Chengyi Zhao; Lan Bai
Journal:  Dig Dis Sci       Date:  2010-09-16       Impact factor: 3.199

6.  PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism.

Authors:  Kelly L Roszko; Tiffany Y Hu; Lori C Guthrie; Beth A Brillante; Michaele Smith; Michael T Collins; Rachel I Gafni
Journal:  J Bone Miner Res       Date:  2021-10-18       Impact factor: 6.390

7.  Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci.

Authors:  Sjur Reppe; Yunpeng Wang; Wesley K Thompson; Linda K McEvoy; Andrew J Schork; Verena Zuber; Marissa LeBlanc; Francesco Bettella; Ian G Mills; Rahul S Desikan; Srdjan Djurovic; Kaare M Gautvik; Anders M Dale; Ole A Andreassen
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

8.  Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13-country patient and caregiver survey.

Authors:  Heide Siggelkow; Bart L Clarke; John Germak; Claudio Marelli; Kristina Chen; Helen Dahl-Hansen; Elizabeth Glenister; Nawal Bent-Ennakhil; Davneet Judge; Katie Mycock; Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2019-12-11       Impact factor: 3.478

Review 9.  Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques.

Authors:  Martina Rauner; Ines Foessl; Melissa M Formosa; Erika Kague; Vid Prijatelj; Nerea Alonso Lopez; Bodhisattwa Banerjee; Dylan Bergen; Björn Busse; Ângelo Calado; Eleni Douni; Yankel Gabet; Natalia García Giralt; Daniel Grinberg; Nika M Lovsin; Xavier Nogues Solan; Barbara Ostanek; Nathan J Pavlos; Fernando Rivadeneira; Ivan Soldatovic; Jeroen van de Peppel; Bram van der Eerden; Wim van Hul; Susanna Balcells; Janja Marc; Sjur Reppe; Kent Søe; David Karasik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

Review 10.  Physical Activity-Dependent Regulation of Parathyroid Hormone and Calcium-Phosphorous Metabolism.

Authors:  Giovanni Lombardi; Ewa Ziemann; Giuseppe Banfi; Sabrina Corbetta
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.